ArticleBreast cancer research : BCR2009
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
Article in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.Medicine · 2018Pooled it
- Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations.Current issues in molecular biology · 2025Review
- Review
- Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice.Journal of clinical medicine · 2021Review
- Liquid Biopsy in Breast Cancer.Geburtshilfe und Frauenheilkunde · 2020Article
- Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors.OncoTargets and therapy · 2020Review
- Recent advances in microfluidic methods in cancer liquid biopsy.Biomicrofluidics · 2019Review
- The Utility of Liquid Biopsy in Central Nervous System Malignancies.Current oncology reports · 2018Review
- Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.Oncotarget · 2017Review
- DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.The Analyst · 2014Article
- Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives.Journal of clinical medicine · 2014Review
- Advances in the medical research and clinical applications on the plasma DNA.Translational pediatrics · 2014Review
- Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Nature reviews. Clinical oncology · 2013Review
- Circulating nucleic acids as biomarkers in breast cancer.Breast cancer research : BCR · 2013Review
- Article
- Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.BMC cancer · 2012Article
- Organ Specific Tumor Markers: What's New?Indian journal of clinical biochemistry : IJCB · 2012Article
- Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.Genome research · 2012Article
- The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy.British journal of cancer · 2012Article
- Minimal residual disease and circulating tumor cells in breast cancer.Breast cancer research : BCR · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe origin and clinical relevance of circulating cell-free tumor DNA in the blood of cancer patients is still unclear. Here we investigated whether the detection of this DNA is related to bone marrow (BM) micrometastasis and tumor recurrence in breast cancer patients.
methodsBM aspirates of 81 primary breast cancer patients were analyzed for the presence of disseminated tumor cells (DTC) by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. PCR-based fluorescence microsatellite analysis was performed for detection of loss of heterozygosity (LOH) at 6 polymorphic markers using cell-free serum DNA. The data were correlated with established risk factors, and patients were followed-up over 6-10 years.
resultsLOH was detected in 33.5% of blood samples. The occurrence of LOH at the entire microsatellite marker set correlated with histopathology (P = 0.05) and grading (P = 0.006) of the primary tumor. The genomic region characterized by marker D9S171 was only affected by LOH in patients with increased tumor stages (pT2-4, P < 0.05) and older age (> or = 55 years, P = 0.05). Kaplan-Meier analysis showed that LOH at D3S1255 (P = 0.009) and D9S171 (P = 0.001) were significantly associated with tumor relapse. In BM, DTC were detected in 39.5% of the patients, and this finding correlated with distant metastases (P < 0.05). Patients with DTC-positive BM had higher DNA yields in their blood than patients with DTC-negative BM (P < 0.05). However, no significant correlations were found between the presence of DTC in BM and the detection of marker-specific LOH on blood DNA.
conclusionsThe detection of LOH on cell-free tumor DNA in blood is unrelated to BM micrometastasis and provides independent information on breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.